date,title,source
Oct-24-18,Immutep Announces Data Presentations at Upcoming Industry Conferences,GlobeNewswire
Oct-30-18,Is Immutep Limited (ASX:IMM) Excessively Paying Its CEO?,Simply Wall St.
Nov-01-18,Operational Update,GlobeNewswire
Nov-12-18,Immutep Presents Positive New Data from Ongoing TACTI-mel Study at Society for Immunotherapy of Cancer (SITC) 2018 Annual Meeting,GlobeNewswire
Nov-27-18,New Data from Ongoing TACTI-mel Study in Unresectable or Metastatic Melanoma Presented at the 4th Annual ICI Europe Summit,GlobeNewswire
Dec-19-18,"Immutep Announces US$5.2 Million Financing Led by U.S. Specialist Healthcare Investor, Altium Capital",GlobeNewswire
Jan-07-19,"Immutep Enters Into Clinical Trial Collaboration, Service and Supply Agreement With CYTLIMIC",GlobeNewswire
Feb-26-19,Immutep to Present at Upcoming Industry Conferences,GlobeNewswire
Mar-04-19,Immutep to Present at Oppenheimers 29th Annual Healthcare Conference,GlobeNewswire
Mar-06-19,Immutep Shareholders Have Enjoyed A 52% Share Price Gain,Simply Wall St.
Mar-06-19,Immutep doses First Patient in TACTI-002 Phase II Trial,GlobeNewswire
Mar-06-19,Immutep Announces Data from Ongoing TACTI-mel Phase I Clinical Trial in Unresectable or Metastatic Melanoma,GlobeNewswire
Mar-06-19,"The Daily Biotech Pulse: Horizon Pharma Under DoJ Radar, FDA Greenlights J&J's Depression Drug, Endologix Reverse Split",Benzinga
Mar-07-19,Immutep Presents Positive IMP761 Preclinical Results at 14th Congress of European Crohns and Colitis Organisation,GlobeNewswire
Mar-18-19,Immutep to Present IMP761 Preclinical Results in Global Webcast,GlobeNewswire
Mar-21-19,Immutep Announces United States Patent Grant for Eftilagimod Alpha in Cancer,GlobeNewswire
Mar-27-19,Immutep to Host Eftilagimod Alpha Clinical Development Update Global Webcast,GlobeNewswire
Apr-08-19,Edison Issues ADR Update on Immutep (IMMP),ACCESSWIRE
Apr-11-19,Immutep Limited (ASX:IMM): Are Analysts Optimistic?,Simply Wall St.
May-10-19,Immutep Announces Upcoming Industry Conference Participation,GlobeNewswire
May-17-19,Immutep Announces Data from Ongoing TACTI-mel Phase I Clinical Trial in Unresectable or Metastatic Melanoma,GlobeNewswire
May-23-19,Immutep Announces European Patent Grant for Eftilagimod Alpha in Chemo-Immunotherapy,GlobeNewswire
Jun-03-19,Immutep Presentation at ASCO 2019,GlobeNewswire
Jun-06-19,INSIGHT: First Patient Dosed in the 4th arm called INSIGHT-004,GlobeNewswire
Jun-13-19,Immutep Completes Recruitment of Initial Cohort in 1st Line NSCLC Patients for TACTI-002 Trial,GlobeNewswire
Jun-21-19,Immutep Announces Australian Patent Granted for Eftilagimod Alpha in Chemo-Immunotherapy,GlobeNewswire
